Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations

Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality worldwide. Recent discoveries identifying circulating antiangiogenic factors-particularly soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin-as key mediators of the maternal syndrome have transformed understanding of its pathogenesis. These insights have led to the development of molecular diagnostics, such as sFlt-1, placental growth factor, and their ratio, now integrated into clinical practice for improved prediction, diagnosis, and management. The serum sFlt-1/placental growth factor is particularly useful for nephrologists for early detection of superimposed preeclampsia in pregnant women with CKD. Emerging therapeutic strategies-including targeted apheresis, recombinant ligands, RNA-based interventions, and small-molecule modulators-offer promise for disease modification. Preeclampsia also confers long-term cardiovascular and kidney risks for mothers and adverse pulmonary outcomes for offspring, underscoring its lifelong effect. Progress in preeclampsia care will depend on sustained scientific innovation and the responsible inclusion of pregnant women in clinical trials to ensure that future diagnostics and therapies are both safe and effective for both mother and baby.